Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines. / Hjorto, Gertrud M.; Larsen, Olav; Steen, Anne; Daugvilaite, Viktorija; Berg, Christian; Fares, Suzan; Hansen, Morten; Ali, Simi; Rosenkilde, Mette M.

In: Frontiers in Immunology, Vol. 7, 568, 09.12.2016.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hjorto, GM, Larsen, O, Steen, A, Daugvilaite, V, Berg, C, Fares, S, Hansen, M, Ali, S & Rosenkilde, MM 2016, 'Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines', Frontiers in Immunology, vol. 7, 568. https://doi.org/10.3389/fimmu.2016.00568, https://doi.org/10.3389/fimmu.2017.00089

APA

Hjorto, G. M., Larsen, O., Steen, A., Daugvilaite, V., Berg, C., Fares, S., ... Rosenkilde, M. M. (2016). Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines. Frontiers in Immunology, 7, [568]. https://doi.org/10.3389/fimmu.2016.00568, https://doi.org/10.3389/fimmu.2017.00089

Vancouver

Hjorto GM, Larsen O, Steen A, Daugvilaite V, Berg C, Fares S et al. Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines. Frontiers in Immunology. 2016 Dec 9;7. 568. https://doi.org/10.3389/fimmu.2016.00568, https://doi.org/10.3389/fimmu.2017.00089

Author

Hjorto, Gertrud M. ; Larsen, Olav ; Steen, Anne ; Daugvilaite, Viktorija ; Berg, Christian ; Fares, Suzan ; Hansen, Morten ; Ali, Simi ; Rosenkilde, Mette M. / Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines. In: Frontiers in Immunology. 2016 ; Vol. 7.

Bibtex

@article{0aaf6b0846ea4a799024faec13b6f816,
title = "Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines",
abstract = "The CCR7 ligands CCL19 and CCL21 are increasingly recognized as functionally different (biased). Using mature human dendritic cells (DCs), we show that CCL19 is more potent than CCL21 in inducing 3D chemotaxis. Intriguingly, CCL21 induces prolonged and more efficient ERK1/2 activation compared with CCL19 and a C-terminal truncated (tailless) CCL21 in DCs. In contrast, tailless-CCL21 displays increased potency in DC chemotaxis compared with native CCL21. Using a CCL21-specific antibody, we show that CCL21, but not tailless-CCL21, accumulates at the cell surface. In addition, removal of sialic acid from the cell surface by neuraminidase treatment impairs ERK1/2 activation by CCL21, but not by CCL19 or tailless-CCL21. Using standard laboratory cell lines, we observe low potency of both CCL21 and tailless-CCL21 in G protein activation and β-arrestin recruitment compared with CCL19, indicating that the tail itself does not improve receptor interaction. Chemokines interact with their receptors in a stepwise manner with ultimate docking of their N-terminus into the main binding pocket. Employing site-directed mutagenesis we identify residues in this pocket of selective CCL21 importance. We also identify a molecular switch in the top of TM7 important for keeping CCR7 in an inactive conformation (Tyr312), as introduction of the chemokine receptor-conserved Glu (or Ala) induces high constitutive activity. Summarized, we show that the interaction of the tail of CCL21 with polysialic acid is needed for strong ERK signaling, whereas it impairs CCL21-mediated chemotaxis and has no impact on receptor docking consistent with the current model of chemokine:receptor interaction. This indicates that future selective pharmacological targeting of CCL19 versus CCL21 should focus on a differential targeting of the main receptor pocket, while selective targeting of tailless-CCL21 versus CCL21 and CCL19 requires targeting of the glycosaminoglycan (GAG) interaction.",
keywords = "CCR7, CCL19, CCL21, tailless-CCL21, dendritic cell, biased signaling, ERK",
author = "Hjorto, {Gertrud M.} and Olav Larsen and Anne Steen and Viktorija Daugvilaite and Christian Berg and Suzan Fares and Morten Hansen and Simi Ali and Rosenkilde, {Mette M.}",
year = "2016",
month = "12",
day = "9",
doi = "10.3389/fimmu.2016.00568",
language = "English",
volume = "7",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines

AU - Hjorto, Gertrud M.

AU - Larsen, Olav

AU - Steen, Anne

AU - Daugvilaite, Viktorija

AU - Berg, Christian

AU - Fares, Suzan

AU - Hansen, Morten

AU - Ali, Simi

AU - Rosenkilde, Mette M.

PY - 2016/12/9

Y1 - 2016/12/9

N2 - The CCR7 ligands CCL19 and CCL21 are increasingly recognized as functionally different (biased). Using mature human dendritic cells (DCs), we show that CCL19 is more potent than CCL21 in inducing 3D chemotaxis. Intriguingly, CCL21 induces prolonged and more efficient ERK1/2 activation compared with CCL19 and a C-terminal truncated (tailless) CCL21 in DCs. In contrast, tailless-CCL21 displays increased potency in DC chemotaxis compared with native CCL21. Using a CCL21-specific antibody, we show that CCL21, but not tailless-CCL21, accumulates at the cell surface. In addition, removal of sialic acid from the cell surface by neuraminidase treatment impairs ERK1/2 activation by CCL21, but not by CCL19 or tailless-CCL21. Using standard laboratory cell lines, we observe low potency of both CCL21 and tailless-CCL21 in G protein activation and β-arrestin recruitment compared with CCL19, indicating that the tail itself does not improve receptor interaction. Chemokines interact with their receptors in a stepwise manner with ultimate docking of their N-terminus into the main binding pocket. Employing site-directed mutagenesis we identify residues in this pocket of selective CCL21 importance. We also identify a molecular switch in the top of TM7 important for keeping CCR7 in an inactive conformation (Tyr312), as introduction of the chemokine receptor-conserved Glu (or Ala) induces high constitutive activity. Summarized, we show that the interaction of the tail of CCL21 with polysialic acid is needed for strong ERK signaling, whereas it impairs CCL21-mediated chemotaxis and has no impact on receptor docking consistent with the current model of chemokine:receptor interaction. This indicates that future selective pharmacological targeting of CCL19 versus CCL21 should focus on a differential targeting of the main receptor pocket, while selective targeting of tailless-CCL21 versus CCL21 and CCL19 requires targeting of the glycosaminoglycan (GAG) interaction.

AB - The CCR7 ligands CCL19 and CCL21 are increasingly recognized as functionally different (biased). Using mature human dendritic cells (DCs), we show that CCL19 is more potent than CCL21 in inducing 3D chemotaxis. Intriguingly, CCL21 induces prolonged and more efficient ERK1/2 activation compared with CCL19 and a C-terminal truncated (tailless) CCL21 in DCs. In contrast, tailless-CCL21 displays increased potency in DC chemotaxis compared with native CCL21. Using a CCL21-specific antibody, we show that CCL21, but not tailless-CCL21, accumulates at the cell surface. In addition, removal of sialic acid from the cell surface by neuraminidase treatment impairs ERK1/2 activation by CCL21, but not by CCL19 or tailless-CCL21. Using standard laboratory cell lines, we observe low potency of both CCL21 and tailless-CCL21 in G protein activation and β-arrestin recruitment compared with CCL19, indicating that the tail itself does not improve receptor interaction. Chemokines interact with their receptors in a stepwise manner with ultimate docking of their N-terminus into the main binding pocket. Employing site-directed mutagenesis we identify residues in this pocket of selective CCL21 importance. We also identify a molecular switch in the top of TM7 important for keeping CCR7 in an inactive conformation (Tyr312), as introduction of the chemokine receptor-conserved Glu (or Ala) induces high constitutive activity. Summarized, we show that the interaction of the tail of CCL21 with polysialic acid is needed for strong ERK signaling, whereas it impairs CCL21-mediated chemotaxis and has no impact on receptor docking consistent with the current model of chemokine:receptor interaction. This indicates that future selective pharmacological targeting of CCL19 versus CCL21 should focus on a differential targeting of the main receptor pocket, while selective targeting of tailless-CCL21 versus CCL21 and CCL19 requires targeting of the glycosaminoglycan (GAG) interaction.

KW - CCR7

KW - CCL19

KW - CCL21

KW - tailless-CCL21

KW - dendritic cell

KW - biased signaling

KW - ERK

UR - http://journal.frontiersin.org/article/10.3389/fimmu.2017.00089/full

U2 - 10.3389/fimmu.2016.00568

DO - 10.3389/fimmu.2016.00568

M3 - Journal article

C2 - 28018341

VL - 7

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 568

ER -

ID: 171656726